LivaNova (NASDAQ:LIVN) Releases FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.300-4.400 for the period, compared to the consensus estimate of 4.150. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LIVN. Stifel Nicolaus set a $85.00 target price on shares of LivaNova in a research report on Wednesday. Freedom Capital raised shares of LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Zacks Research raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Barclays boosted their target price on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of LivaNova in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and an average price target of $83.50.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded down $0.31 during midday trading on Friday, hitting $75.47. The company had a trading volume of 274,175 shares, compared to its average volume of 775,277. LivaNova has a 12-month low of $48.57 and a 12-month high of $85.76. The company has a fifty day moving average of $79.60 and a two-hundred day moving average of $70.71. The company has a market cap of $4.15 billion, a price-to-earnings ratio of 22.29 and a beta of 0.86. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. The business had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a return on equity of 16.36% and a net margin of 12.82%.The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.05 EPS. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. On average, equities research analysts expect that LivaNova will post 3.73 EPS for the current fiscal year.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. UMB Bank n.a. boosted its stake in LivaNova by 22.6% in the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after acquiring an additional 179 shares in the last quarter. Parallel Advisors LLC lifted its stake in LivaNova by 28.8% in the fourth quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock valued at $78,000 after buying an additional 283 shares during the last quarter. California State Teachers Retirement System boosted its stake in LivaNova by 0.9% during the 2nd quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock worth $2,260,000 after purchasing an additional 458 shares during the period. EverSource Wealth Advisors LLC increased its stake in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the period. Finally, State of Wyoming purchased a new stake in shares of LivaNova during the second quarter worth approximately $31,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.